tiprankstipranks
Trending News
More News >
Vera Therapeutics (VERA)
NASDAQ:VERA
US Market

Vera Therapeutics (VERA) Stock Forecast & Price Target

Compare
549 Followers
See the Price Targets and Ratings of:

VERA Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Vera
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VERA Stock 12 Month Forecast

Average Price Target

$66.58
▲(193.95%Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $66.58 with a high forecast of $100.00 and a low forecast of $23.00. The average price target represents a 193.95% change from the last price of $22.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","41":"$41","61":"$61","81":"$81","101":"$101"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,41,61,81,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.74,36.99076923076923,42.24153846153846,47.49230769230769,52.74307692307693,57.99384615384615,63.244615384615386,68.49538461538462,73.74615384615385,78.99692307692308,84.2476923076923,89.49846153846154,94.74923076923078,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.74,34.42,37.1,39.78,42.46,45.14,47.82,50.5,53.18,55.86,58.54,61.22,63.900000000000006,{"y":66.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.74,31.067692307692305,30.395384615384614,29.72307692307692,29.05076923076923,28.378461538461536,27.706153846153846,27.033846153846152,26.361538461538462,25.689230769230768,25.016923076923078,24.344615384615384,23.67230769230769,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.35,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.32,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$66.58Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on VERA
Anupam RamaJ.P. Morgan
J.P. Morgan
$68$56
Buy
147.24%
Upside
Reiterated
06/13/25
J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Wedbush
$32$23
Hold
1.55%
Upside
Reiterated
06/09/25
Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)
LifeSci Capital Analyst forecast on VERA
Rami KatkhudaLifeSci Capital
LifeSci Capital
$70
Buy
209.05%
Upside
Reiterated
06/07/25
Buy Rating for Vera Therapeutics: Promising Atacicept Data and Market Potential in IgAN Treatment
Evercore ISI Analyst forecast on VERA
Liisa BaykoEvercore ISI
Evercore ISI
$75
Buy
231.13%
Upside
Reiterated
06/06/25
Vera Therapeutics (VERA) Gets a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on VERA
Arthur He CFAH.C. Wainwright
H.C. Wainwright
$75$85
Buy
275.28%
Upside
Reiterated
06/06/25
Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment
TD Cowen Analyst forecast on VERA
Ritu BaralTD Cowen
TD Cowen
$60
Buy
164.90%
Upside
Reiterated
06/06/25
TD Cowen Sticks to Their Buy Rating for Vera Therapeutics (VERA)
Guggenheim Analyst forecast on VERA
Vamil DivanGuggenheim
Guggenheim
$65
Buy
186.98%
Upside
Reiterated
06/06/25
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Raymond James Analyst forecast on VERA
Ryan DeschnerRaymond James
Raymond James
$73
Buy
222.30%
Upside
Reiterated
06/06/25
Vera Therapeutics (VERA) Receives a Buy from Raymond James
Wells Fargo Analyst forecast on VERA
Mohit BansalWells Fargo
Wells Fargo
$70
Buy
209.05%
Upside
Assigned
06/02/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (NYSE: WST), Blueprint Medicines (NASDAQ: BPMC) and Vera Therapeutics (NASDAQ: VERA)
Scotiabank Analyst forecast on VERA
Greg HarrisonScotiabank
Scotiabank
$55$65
Buy
186.98%
Upside
Reiterated
06/02/25
Vera Therapeutics price target raised to $65 from $55 at ScotiabankVera Therapeutics price target raised to $65 from $55 at Scotiabank
Jefferies Analyst forecast on VERA
Farzin HaqueJefferies
Jefferies
$57
Buy
151.66%
Upside
Assigned
06/02/25
Vera Therapeutics: Promising Phase III Results and Strategic Positioning Justify Buy Rating
Cantor Fitzgerald Analyst forecast on VERA
Pete StavropoulosCantor Fitzgerald
Cantor Fitzgerald
$100
Buy
341.50%
Upside
Reiterated
05/29/25
Cantor Fitzgerald Keeps Their Buy Rating on Vera Therapeutics (VERA)
Goldman Sachs Analyst forecast on VERA
Paul ChoiGoldman Sachs
Goldman Sachs
$58
Buy
156.07%
Upside
Reiterated
02/14/25
Vera reaction to competitor IgAN update 'overdone,' says Goldman SachsVera reaction to competitor IgAN update 'overdone,' says Goldman Sachs
Wolfe Research Analyst forecast on VERA
Andy ChenWolfe Research
Wolfe Research
$49
Buy
116.34%
Upside
Initiated
02/03/25
Vera Therapeutics initiated with an Outperform at Wolfe ResearchVera Therapeutics initiated with an Outperform at Wolfe Research
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on VERA
Anupam RamaJ.P. Morgan
J.P. Morgan
$68$56
Buy
147.24%
Upside
Reiterated
06/13/25
J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Wedbush
$32$23
Hold
1.55%
Upside
Reiterated
06/09/25
Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)
LifeSci Capital Analyst forecast on VERA
Rami KatkhudaLifeSci Capital
LifeSci Capital
$70
Buy
209.05%
Upside
Reiterated
06/07/25
Buy Rating for Vera Therapeutics: Promising Atacicept Data and Market Potential in IgAN Treatment
Evercore ISI Analyst forecast on VERA
Liisa BaykoEvercore ISI
Evercore ISI
$75
Buy
231.13%
Upside
Reiterated
06/06/25
Vera Therapeutics (VERA) Gets a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on VERA
Arthur He CFAH.C. Wainwright
H.C. Wainwright
$75$85
Buy
275.28%
Upside
Reiterated
06/06/25
Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment
TD Cowen Analyst forecast on VERA
Ritu BaralTD Cowen
TD Cowen
$60
Buy
164.90%
Upside
Reiterated
06/06/25
TD Cowen Sticks to Their Buy Rating for Vera Therapeutics (VERA)
Guggenheim Analyst forecast on VERA
Vamil DivanGuggenheim
Guggenheim
$65
Buy
186.98%
Upside
Reiterated
06/06/25
Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Raymond James Analyst forecast on VERA
Ryan DeschnerRaymond James
Raymond James
$73
Buy
222.30%
Upside
Reiterated
06/06/25
Vera Therapeutics (VERA) Receives a Buy from Raymond James
Wells Fargo Analyst forecast on VERA
Mohit BansalWells Fargo
Wells Fargo
$70
Buy
209.05%
Upside
Assigned
06/02/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (NYSE: WST), Blueprint Medicines (NASDAQ: BPMC) and Vera Therapeutics (NASDAQ: VERA)
Scotiabank Analyst forecast on VERA
Greg HarrisonScotiabank
Scotiabank
$55$65
Buy
186.98%
Upside
Reiterated
06/02/25
Vera Therapeutics price target raised to $65 from $55 at ScotiabankVera Therapeutics price target raised to $65 from $55 at Scotiabank
Jefferies Analyst forecast on VERA
Farzin HaqueJefferies
Jefferies
$57
Buy
151.66%
Upside
Assigned
06/02/25
Vera Therapeutics: Promising Phase III Results and Strategic Positioning Justify Buy Rating
Cantor Fitzgerald Analyst forecast on VERA
Pete StavropoulosCantor Fitzgerald
Cantor Fitzgerald
$100
Buy
341.50%
Upside
Reiterated
05/29/25
Cantor Fitzgerald Keeps Their Buy Rating on Vera Therapeutics (VERA)
Goldman Sachs Analyst forecast on VERA
Paul ChoiGoldman Sachs
Goldman Sachs
$58
Buy
156.07%
Upside
Reiterated
02/14/25
Vera reaction to competitor IgAN update 'overdone,' says Goldman SachsVera reaction to competitor IgAN update 'overdone,' says Goldman Sachs
Wolfe Research Analyst forecast on VERA
Andy ChenWolfe Research
Wolfe Research
$49
Buy
116.34%
Upside
Initiated
02/03/25
Vera Therapeutics initiated with an Outperform at Wolfe ResearchVera Therapeutics initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vera Therapeutics

1 Month
xxx
Success Rate
11/20 ratings generated profit
55%
Average Return
+4.08%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of +4.08% per trade.
3 Months
xxx
Success Rate
9/17 ratings generated profit
53%
Average Return
+37.45%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +37.45% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
7/17 ratings generated profit
41%
Average Return
+81.32%
reiterated a buy rating 17 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +81.32% per trade.
2 Years
xxx
Success Rate
8/17 ratings generated profit
47%
Average Return
+37.36%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 47.06% of your transactions generating a profit, with an average return of +37.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERA Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
15
18
15
16
28
Buy
3
2
2
0
0
Hold
0
0
0
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
20
17
17
30
In the current month, VERA has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VERA average Analyst price target in the past 3 months is 66.58.
Each month's total comprises the sum of three months' worth of ratings.

VERA Financial Forecast

VERA Earnings Forecast

Next quarter’s earnings estimate for VERA is -$0.82 with a range of -$0.90 to -$0.69. The previous quarter’s EPS was -$0.81. VERA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year VERA has Outperformed its overall industry.
Next quarter’s earnings estimate for VERA is -$0.82 with a range of -$0.90 to -$0.69. The previous quarter’s EPS was -$0.81. VERA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year VERA has Outperformed its overall industry.
No data currently available

VERA Sales Forecast

Next quarter’s sales forecast for VERA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VERA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year VERA has Preformed in-line its overall industry.
Next quarter’s sales forecast for VERA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VERA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year VERA has Preformed in-line its overall industry.

VERA Stock Forecast FAQ

What is VERA’s average 12-month price target, according to analysts?
Based on analyst ratings, Vera Therapeutics’s 12-month average price target is 66.58.
    What is VERA’s upside potential, based on the analysts’ average price target?
    Vera Therapeutics has 193.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VERA a Buy, Sell or Hold?
          Vera Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Vera Therapeutics’s price target?
            The average price target for Vera Therapeutics is 66.58. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $23.00. The average price target represents 193.95% Increase from the current price of $22.65.
              What do analysts say about Vera Therapeutics?
              Vera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of VERA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis